TOPLINE: A discrete choice experiment (DCE) revealed no meaningful difference in preference between dual biologic therapy (DBT) or monotherapy among patients with inflammatory bowel disease (IBD) who had failed or were taking advanced treatments, with patients willing to accept a 17.5% risk for serious infection for better remission prospects. METHODOLOGY: Encouraging initial studies about DBT […]
The post Difficult-to-Treat IBD Patients Prefer Dual Biologic Therapy first appeared on News Health.
Author : News Health
Publish date : 2025-03-12 12:12:00
Copyright for syndicated content belongs to the linked Source.